<DOC>
	<DOCNO>NCT01508026</DOCNO>
	<brief_summary>To evaluate efficacy safety fixed-dose combination nebivolol valsartan compare monotherapy placebo patient stage 1 stage 2 hypertension .</brief_summary>
	<brief_title>Study Efficacy Safety Combination Two FDA Approved Oral Medications , Nebivolol Valsartan Treatment Stage 1 2 Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Male female outpatient age 18 year Patients diagnose stage 1 stage 2 essential hypertension Normal physical examination finding , electrocardiogram ( ECG ) result chest xray ; abnormal finding judge Investigator clinically significant Secondary hypertension severe hypertension Clinically significant cardiovascular disease heart failure Clinical significant respiratory disease would prohibit use beta blocker A medical contraindication discontinue current antihypertensive therapy History Type 1 diabetes mellitus History Severe Mental Illness except mild depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Stage 1</keyword>
	<keyword>Stage 2</keyword>
	<keyword>Hypertension</keyword>
</DOC>